In its most recent tie-up with Boehringer Ingelheim GMBH, Eli Lilly & Co. has inked a research collaboration to test its late-stage cancer asset with an early-stage compound from its partner. The tie-up has the potential to advance both companies in the oncology space.
Lilly and BI announced July 13 that they will test Lilly's cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib with BI's insulin-like...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
